*Aquesta Uropathology

†University of Queensland

§Department of Pathology and Molecular Medicine, Wesley Hospital, Brisbane

∥Redcliffe Hospital, Redcliffe, QLD, Australia

‡Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden

¶Malaghan Institute of Medical Research, Wellington, New Zealand

Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.

Correspondence: Brett Delahunt, MD, FRCPA, Aquesta Uropathology, 21 Lissner Street, Toowong, QLD 4066, Australia (e-mail: [email protected]).